Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation
Authors:
Open Access
- 5 December 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e82943
Abstract
The treatment of patients with MDR- and XDR-TB is usually more complex, toxic and costly and less effective than treatment of other forms of TB. However, there is little information available on risk factors for poor outcomes in patients with MDR- and XDR-TB in China. We retrospectively analyzed the clinical records of HIV-negative TB Patients with culture-proven MDR- or XDR-TB who were registered from July 2006 to June 2011 at five large-scale Tuberculosis Specialized Hospitals in China. Among 1662 HIV-seronegative TB cases which were culture-positive for M. tuberculosis complex and had positive sputum-smear microscopy results, 965 cases (58.1%) were DR-TB, and 586 cases (35.3%) were classified as having MDR-TB, accounting for 60.7% of DR-TB. 169 cases (10.2%) were XDR-TB, accounting for 17.5% of DR-TB, 28.8% of MDR-TB. The MDR-TB patients were divided into XDR-TB group (n=169) and other MDR-TB group (non-XDR MDR-TB) (n=417). In total, 240 patients (40.95%) had treatment success, and 346 (59.05%) had poor treatment outcomes. The treatment success rate in other MDR-TB group was 52.2%, significantly higher than that in the XDR-TB group (13%, P2 (OR, 2.185; 95% CI, 1.372-3.478, P<0.001), XDR (OR, 13.368; 95% CI, 6.745-26.497, P<0.001), retreatment (OR, 0.171; 95% CI, 0.093-0.314, P<0.001), diabetes (OR, 0.305; 95% CI, 0.140-0.663, P=0.003), tumor (OR, 0.095; 95% CI, 0.011-0.795, P=0.03), decreased albumin (OR, 0.181; 95% CI, 0.118-0.295, P<0.001), cavitation (OR, 0.175; 95% CI, 0.108-0.286, P<0.001). The patients with MDR-TB and XDR-TB have poor treatment outcomes in China.The presence of extensive drug resistance, low BMI, hypoalbuminemia, comorbidity, cavitary disease and previous anti-TB treatment are independent prognostic factors for poor outcome in patients with MDR-TB.Keywords
This publication has 35 references indexed in Scilit:
- [The prevalence of pulmonary tuberculosis in a national survey across China in 2010].2012
- National Survey of Drug-Resistant Tuberculosis in ChinaNew England Journal of Medicine, 2012
- Population-based surveillance of extensively drug-resistant tuberculosis in Shandong Province, China [Short communication]The International Journal of Tuberculosis and Lung Disease, 2012
- Treatment Outcomes among Patients with Extensively Drug‐Resistant Tuberculosis: Systematic Review and Meta‐AnalysisClinical Infectious Diseases, 2010
- Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosisThe Lancet, 2010
- Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia.2009
- Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Treatment Outcomes for HIV‐Uninfected Patients with Multidrug‐Resistant and Extensively Drug‐Resistant TuberculosisClinical Infectious Diseases, 2008
- Impact of Extensive Drug Resistance on Treatment Outcomes in Non-HIV-Infected Patients with Multidrug-Resistant TuberculosisClinical Infectious Diseases, 2007
- Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.2005